AI Mammography in 2026: Breast Cancer Detection Just Got 20% Better
By Dr. Sarah Mitchell, Respiratory Equipment Specialist · Published 2026-05-15 · 9 min read
FDA-cleared AI systems like Lunit INSIGHT MMG and Therapixel are catching cancers radiologists miss — while cutting recall rates.
Radiologist + AI Beats Either Alone
AI-assisted mammography is now FDA-cleared and used in over 1,000 US breast imaging centers. The MASAI trial (Sweden, 80,000 women) showed AI-assisted reads detected 20% more cancers while reducing the radiologist workload 44%.
Leading 2026 Systems
- Lunit INSIGHT MMG (South Korea)
- Therapixel MammoScreen (France)
- Volpara Health Risk Pathways (NZ/US)
- iCAD ProFound AI
Who Benefits Most
- Dense breast tissue patients (40% of women — traditional mammography misses 30-50% of cancers here)
- Younger women with first-degree family history
- Underserved areas with radiologist shortages
Action Steps
- Ask your imaging center if they use AI assistance
- Know your breast density (mandatory disclosure since 2024)
- Consider supplemental MRI or contrast-enhanced mammography if dense breasts + high risk
Mammography compression briefly raises blood pressure and respiratory rate; if you use portable oxygen, bring it to your appointment.